Our findings suggests that BRCA1 promoter methylation is a better predictor of recurrence and survival than factors such as tumor size, lymph node metastasis, histological grade, and age in early-stage breast cancer. This evidence concerns the gene BRCA1 and metastatic malignant neoplasm in the lymph nodes.